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Abstract: Schistosomiasis is a neglected tropical disease caused by parasitic blood flukes of the
genus Schistosoma, which kills 300,000 people every year in developing countries, and there
is no vaccine. Recently, we have shown that cholinesterases (ChEs)—enzymes that regulate
neurotransmission—from Schistosoma mansoni are expressed on the outer tegument surface and
present in the excretory/secretory products of larval schistosomula and adult worms, and are essential
for parasite survival in the definitive host, highlighting their utility as potential schistosomiasis
vaccine targets. When treated in vitro with anti-schistosome cholinesterase (SmChE) IgG, both
schistosomula and adult worms displayed significantly decreased ChE activity, which eventually
resulted in parasite death. Vaccination with individual SmChEs, or a combination of all three SmChEs,
significantly reduced worm burdens in two independent trials compared to controls. Average adult
worm numbers and liver egg burdens were significantly decreased for all vaccinated mice across both
trials, with values of 29–39% and 13–46%, respectively, except for those vaccinated with SmAChE1
in trial 1. Egg viability, as determined by egg hatching from liver homogenates, was significantly
reduced in the groups vaccinated with the SmChE cocktail (40%) and SmAChE2 (46%). Furthermore,
surviving worms from each vaccinated group were significantly stunted and depleted of glycogen
stores, compared to controls. These results suggest that SmChEs could be incorporated into a vaccine
against schistosomiasis to reduce the pathology and transmission of this debilitating disease.
Keywords: schistosomiasis; vaccine; cholinesterase
1. Introduction
Schistosomiasis is caused by an infection with parasitic blood flukes of the genus Schistosoma,
killing 300,000 people every year and infecting hundreds of millions more in developing countries [1].
The disease is spread when humans come into contact with the water-borne, infective stage of the
parasite—the cercariae—which penetrate the skin and migrate through the vasculature and lungs
before entering the venous system, where they become sexually mature adults that pair and mate.
Eggs laid by the female are then passed in the urine or feces to the environment, which continues the
transmission of schistosomiasis [1]. Eggs are deposited in tissues and organs of the host, such as the
liver, and much of the disease pathology is a product of the immune response against these trapped
ova, where the ensuing granulomatous lesions lead to fibrosis, which can cause severe circulatory
impairment of the affected organs [2].
Despite decades of concentrated research, there is still no effective and practical vaccine against
the disease [3]. Furthermore, mass chemotherapy using praziquantel (PZQ)—the only effective
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anti-schistosomal drug—is complicated by rapid and frequent reinfection [4]. There is also evidence
suggesting that PZQ may be having a reduced efficacy in the treatment of infection [5].
So far, a considerable number of schistosome antigens have been identified and tested as vaccines
and, although a number of these vaccine candidates (for example, SmTSP-2, Sm14, Sm29, SmCB1,
and Smp80) have shown promising efficacy in animal models and are in various stages of pre-clinical
or clinical development, none have been approved for licensure [reviewed in [3]].
Due to the fundamental roles they play in parasite biology (reviewed in [6]), schistosome
cholinesterases (SmChEs) have been posited as intervention targets against schistosomiasis and there
are several indications to support the feasibility of their use as vaccines. Firstly, SmChEs have been
localized to the tegument (outer, host-exposed surface) of schistosomula and adult worms [7,8] and
anti-SmChE antibodies have been shown to bind to and kill schistosomula [9], suggesting that the
enzymes are accessible to immune attack. Anti-SmChE antibodies also showed no cross-reactivity
against human acetylcholinesterase (AChE) [7], indicating that a vaccine safe for human use could be
designed. Thirdly, protein array studies have detected significantly high levels of antibodies to SmChEs
in humans exhibiting a resistance and low pathology to schistosomiasis, suggesting an involvement
of these antibodies in a protective anti-schistosomal response [10,11]. Most of these studies have
employed the use of anti-SmChE antibodies raised against biochemically purified material, so the
vaccine efficacy of any one SmChE paralog remains to be elucidated.
A recent study by us [8] documented the existence of three SmChE paralogs (two
acetylcholinesterases—smache1 and smache2—and one butyrylcholinesterase (BChE)—smbche1), and we
showed that each molecule localized to the tegument of adults and schistosomula and demonstrated,
through RNAi-mediated suppression in vitro and in vivo, that each paralog was essential to parasite
survival. We also reported a significant reduction in the glucose-scavenging ability of silenced parasites,
providing evidence for the involvement of tegumental AChE in the mediation of exogenous glucose
uptake, which has also been documented by other studies [12–14]. Despite the fundamental roles that
SmChEs appear to play in parasitism, it remains to be determined which SmChE paralogs are effective
vaccine targets in Schistosoma mansoni.
Herein, we demonstrate that purified IgG against each of the three SmChE paralogs inhibits ChE
activity in both larval and adult worms in vitro, which results in eventual parasite death. Furthermore,
we document the efficacy of these SmChEs, when administered as recombinant vaccines in isolation
or as a triple combination, in reducing the parasite burden, stunting worm growth, and decreasing
egg viability.
2. Materials and Methods
2.1. Ethics Statement
All experimental procedures reported in the study were approved by the James Cook University
(JCU) animal ethics (Ethics approval numbers A2391). Mice were maintained in cages in the university’s
quarantine facility (Q2152) for the duration of the experiments. The study protocols were in accordance
with the 2007 Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and
the 2001 Queensland Animal Care and Protection Act.
2.2. Parasites
Biomphalaria glabrata snails infected with S. mansoni (NMRI strain) were obtained from the
Biomedical Research Institute (BRI) (MD, USA). Cercariae were shed by exposure to light at 28 ◦C for
1.5 h and mechanically transformed to obtain schistosomula [15]. To obtain adult worms, 6-8-week-old
male BALB/c mice (Animal Resource Centre, WA) were infected with 120 cercariae via tail penetration
and parasites harvested by vascular perfusion at 7-8 weeks post-infection [16].
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2.3. Recombinant Protein Expression and Purification
Complete open reading frames (ORFs) for smache1, smbche1, and smache2 were synthesized by
Genewiz. Attempts to express full-length sequences in E. coli were unsuccessful, so primer sets
incorporating NdeI (forward primer) and XhoI restriction enzyme sites (reverse primer) were designed
to amplify partial, non-conserved regions of each smche [8], which might prove more amenable
to expression. Sequences (containing NdeI/ XhoI sites) for each SmChE were amplified from each
full-length template by a polymerase chain reaction (PCR) and cloned into the pET41a expression
vector (Novagen) such that the N-terminal GST tag was removed. Protein expression was induced
for 24 h in E. coli BL21 (DE3) by the addition of 1 mM isopropyl beta-D-1-thiogalactopyranoside
(IPTG) using standard methods. Cultures were harvested by centrifugation (8000× g for 20 min at
4 ◦C), re-suspended in 50 mL lysis buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 40 mM
imidazole) and stored at −80 ◦C. Cell pellets were lysed by three freeze-thaw cycles at −80 and 42 ◦C,
followed by sonication on ice (10 × 5 s pulses [70% amplitude] with 30 s rest periods between each
pulse) with a Qsonica Sonicator. Triton X-100 was added to each lysate at a final concentration of 3%
and incubated for 1 h at 4 ◦C with end-over-end mixing. Insoluble material (containing SmChEs) was
pelleted by centrifugation at 20,000× g for 20 min at 4 ◦C. The supernatant was discarded, and inclusion
bodies (IBs) were washed twice by resuspension in 30 mL of lysis buffer, followed by centrifugation at
20,000× g for 20 min at 4 ◦C. IBs were then solubilized sequentially by resuspension in 25 mL lysis
buffers containing either 2, 4, or 8 M urea; end-over-end mixing overnight at 4 ◦C; and centrifugation
at 20,000× g for 20 min at 4 ◦C. Finally, supernatant containing solubilized IBs was diluted 1:4 in lysis
buffer containing 8M urea and filtered through a 0.22 µm membrane (Millipore). Solubilized IBs were
purified by immobilized metal affinity chromatography (IMAC) by loading onto a prepacked 1 mL
His-Trap HP column (GE Healthcare) equilibrated with lysis buffer containing 8M urea at a flow rate
of 1 mL/min using an AKTA-pure-25 FPLC (GE Healthcare). After washing with 20 mL lysis buffer
containing 8M urea, bound His-tagged proteins were eluted using the same buffer with a stepwise
gradient of 50-250 mM imidazole (50 mM steps). Fractions containing SmChEs (as determined by
SDS-PAGE) were pooled and concentrated using Amicon Ultra-15 centrifugal devices with a 3 kDa
MWCO and quantified using the Pierce BCA Protein Assay kit. The final concentration of each SmChE
was adjusted to 1 mg/mL and proteins were aliquoted and stored at −80 ◦C.
2.4. Generation of Anti-Smche Antisera and Purification of IgG
Three groups of five male BALB/c mice (6-week-old) were intraperitoneally immunized with
either SmAChE1, SmBChE1, or SmAChE2 subunits (50 µg/mouse). Antigens were mixed with an
equal volume of Imject alum adjuvant (Thermofisher) and administered three times, two weeks apart.
Two weeks after the final immunization, mice were sacrificed and blood was collected via cardiac
puncture. Blood from all mice in each group was pooled and serum was separated by centrifugation
after clotting and stored at −20 ◦C. Polyclonal antibodies were purified from mouse sera using Protein
A Sepharose-4B (Thermofisher), according to the manufacturer’s instructions. Serum from naïve mice
was similarly processed.
2.5. Effect of Polyclonal Anti-SmChE IgG on Larval Worms
Newly transformed schistosomula (1000/mL) were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (supplemented with 4 × AA) at 37 ◦C and 5% CO2 in the presence of 50 µg of either
anti-SmAChE1, SmBChE1, or SmAChE2 polyclonal IgG or a combination of all three antibodies
(equal amounts—50 µg total). Separate sets of parasites were similarly incubated with 50 µg of naïve
mouse IgG, which served as a control. After 2 and 14 h (separate experiments were conducted for
each timepoint), 300 schistosomula from each experiment were removed and assessed for viability
using Trypan Blue exclusion (100 parasites in triplicate) [17]. Surface and secreted ChE activity was
measured using the remaining parasites by incubating them in 0.5 mL of assay buffer (0.1M sodium
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phosphate, pH 7.4, 2 mM acetylthiocholine [AcSCh], or 2 mM butyrylthiocholine [BcSCh], and 0.5 mM
5, 5′-dithio-bis 2-nitrobenzoc acid [DTNB]) and monitoring the absorbance increase (AcSCh conversion
or BcSCh conversion) over 1 h at 405 nm in a Polarstar Omega microplate reader (BMG Labtech).
Parasites cultured with naïve IgG served as a negative control. Data are presented as the average of
two biological and three technical replicates ± SEM.
2.6. Effect of Polyclonal Anti-SmChE IgG on Adult Worms
Enzyme inhibitory effects 24 h after the addition of IgG (including naïve IgG) were measured
as for schistosomula using five pairs of freshly perfused adult worms in 1 mL of media. Data are
presented as the average of two biological and two technical (four total) replicates ± SEM. To investigate
the effects of polyclonal anti-SmChE IgG on the worm viability, ten pairs of worms were similarly
incubated with antibodies for 10 days, monitored every 24 h for motility by microscopic examination,
and considered dead if no movement was seen. To measure the effect of polyclonal anti-SmChE IgG on
glucose uptake, ten pairs of worms were similarly incubated with antibodies for 24 h and transferred
to DMEM (1000 mg/L) and then the media glucose concentration was measured over a 24 h period
using a glucose assay kit (Sigma). Glucose levels were expressed relative to media collected from
worms which received naïve IgG (negative control). Data are presented as the average of two biological
replicates ± SEM.
2.7. Anti-SmChE IgG Responses in S. mansoni-Infected Mice during Infection and Before and After
PZQ Treatment
Sera from S. mansoni-infected male BALB/c mice (6-8 weeks) (n = 5) were collected at day 3, 14, 28,
42, and 56 post infection (p.i.) to assess anti-SmChE responses during the course of parasite infection.
In a separate experiment, sera from S. mansoni-infected male BALB/c mice (6-8 weeks) (n = 11) were
collected at 5 weeks p.i. and mice were then treated orally with PZQ (100 mg/kg) at 35, 37, and 39 days
p.i. Sera were again collected at day 49 p.i. (2 weeks post-PZQ treatment). Anti-SmChE responses
during infection and before and after PZQ treatment were screened by ELISA with plated SmChEs
(100 ng/well) using standard methods. The cutoff value for each dilution was established as three times
the mean OD of the naïve sera for that dilution and the endpoint was defined as the highest dilution
above the cutoff value.
2.8. Vaccine Trials
Five groups of 10 male BALB/c mice (6-8 weeks) were immunized intraperitoneally on day
1 (50 µg/mouse) with either SmAChE1, SmBChE1, SmAChE2, a combination of all three SmChEs
(17 µg each—50 µg total), or PBS, each formulated with an equal volume of Imject alum adjuvant
(Thermofisher) and 5µg of CpG ODN1826 (InvivoGen). Immunizations were repeated on day 15
and 29 and each mouse was infected by tail penetration with 120 S. mansoni cercariae [18] on day 43.
Two independent trials were performed to ensure reproducibility. Blood was sampled at day 28 and 42
and on the day of a necropsy, to determine pre- and post-challenge antibody titers.
2.9. Mouse Necropsy and Estimation of Worm and Egg Burden
Mice were necropsied at day 91 (7 weeks p.i.) and worms were harvested by vascular perfusion
and counted. Worms from the mice in each group were pooled and a random sample of each pool was
photographed and measured using ImageJ software. Livers were removed and halved, with one half
weighed and digested for 5 h with 5% KOH at 37 ◦C with shaking. Schistosome eggs from digested
livers were concentrated by centrifugation at 1000× g for 10 min and re-suspended in 1 mL of 10%
formalin. The number of eggs in a 5 µL aliquot was counted in triplicate and the number of eggs per
gram (EPG) of the liver was calculated. Small intestines were removed and cleaned of debris before
being weighed and digested as per the liver halves. Eggs were also similarly concentrated and counted
to calculate the intestinal EPG.
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2.10. Egg Viability Assays
The other half of each liver was pooled according to the group, homogenized in H2O, and placed
in identical foil-covered volumetric flasks under bright light to hatch eggs released from the livers.
After 1 h, the number of miracidia in 10 × 50 µL aliquots of H2O (sampled from the extreme top of
each flask) were counted. The number of eggs in each flask at the start of the hatching experiment was
determined by liver EPG calculations, allowing the egg hatching index of each group to be calculated
by expressing the hatched eggs (miracidia) as a percentage of the total eggs [13].
2.11. Glucose Consumption and Glycogen Storage Assays
Five pairs of freshly perfused worms from each vaccinated group were cultured in DMEM
(1000 mg/L glucose). Media (50 µL) from each experiment was collected after 24 h, and the amount of
glucose was quantified using a colorimetric glucose assay kit (Sigma), according to the manufacturer’s
instructions. Glucose levels were expressed relative to media collected from worms recovered
from PBS-treated mice (negative control). To measure the glycogen content of these worms, Triton
X-100-soluble extracts of each group of five pairs of worms (made by homogenizing the parasites in
1% Triton X-100, 40 mM Tris-HCl, pH 7.4, mixing overnight at 4 ◦C, and collecting the supernatant
by centrifugation at 15,000× g for 1 h at 4 ◦C) were assayed for glycogen in a modified procedure
described by Gomez-Lechon et al. [19]. Briefly, 0.2 M sodium acetate, pH 4.8, was added to 30 µg
parasite extract and 50 µL glucoamylase (10 U/mL) to make a reaction volume of 150 µL. The mixture
was incubated at 40 ◦C for 2 h with shaking at 100 rpm, 40 µL was added to a new microplate with
10 µL 0.25 M NaOH, and the amount of glucose was quantified using the colorimetric glucose assay
kit. Only worms from trial 1 were available for these experiments. Extracts were made from triplicate
sets of parasites and assays were performed three times. Data are presented as the average of each
triplicate biological and technical experiment ± SEM.
2.12. Experiments Involving Sera from Vaccinated Mice
Sera were collected from all mice in each group before cercarial challenge and at necropsy. Serum
anti-SmChE IgG titers were measured by ELISA against plated SmChEs using standard methods.
The cutoff value for each dilution was established as three times the mean OD of the naïve sera for that
dilution and the endpoint was defined as the highest dilution above the cutoff value.
To assess whether vaccination-induced antibodies would interact with host serum AChE or BChE,
the AChE and BChE activity of pre-challenge sera from all vaccinated and control mice was measured
by the Ellman assay. Briefly, 1 µL of pre-challenge serum from each mouse was added to 200 µL assay
buffer (0.1M sodium phosphate, pH 7.4, 2 mM acetylthiocholine [AcSCh], or 2 mM butyrylthiocholine
[BcSCh], and 0.5 mM 5, 5′-dithio-bis 2-nitrobenzoc acid [DTNB]) and the absorbance increase (AcSCh
conversion or BcSCh conversion) was monitored over 20 min at 405 nm in a Polarstar Omega microplate
reader (BMG Labtech). Data are presented as the average of three technical replicates ± SEM.
2.13. Statistical analyses
Statistical differences for all experiments in this chapter were calculated by the Student’s t test using
GraphPad Prism 7 software. Results are expressed as the mean ± standard error of the mean (SEM).
3. Results
3.1. Anti-SmChE Polyclonal Antibodies Block Enzyme Activity and Decrease the Viability of Larval S. mansoni
in Vitro
To determine the ability of anti-SmChE-specific polyclonal antibodies to inhibit ChE activity
in S. mansoni, and the effect this had on parasite viability, we studied the effects of paralog-specific
antibodies on schistosomula at two different timepoints. Treating schistosomula with anti-SmAChE1
IgG, anti-SmAChE2 IgG, or a cocktail of all three anti-SmChE IgGs caused a significant inhibition (p ≤
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0.01) of AChE activity of 56.2%, 57.1%, and 59.74%, respectively, 2 h after treatment, in comparison
with the naïve IgG control (Figure 1A). When schistosomula were incubated with anti-SmBChE1 IgG
or a cocktail of all three anti-SmChE IgGs for 2 h, the BChE activity was inhibited by 37.4% (p ≤ 0.01)
and 49.3% (p ≤ 0.001), respectively, compared to the control (Figure 1B). Schistosomula viability was
not significantly affected at this timepoint (Figure 1C). Extending the treatment with anti-SmAChE1
IgG, anti-SmAChE2 IgG, or a cocktail of all three anti-SmChE IgGs for 14 h significantly decreased
(p ≤ 0.001) the AChE activity by 66.9%, 70.5%, and 72.6%, respectively, compared to the control
(Figure 1D). Similarly, when schistosomula were incubated with anti-SmBChE1 IgG or a cocktail of all
three anti-SmChE IgGs for 14 h, the BChE activity decreased significantly (p ≤ 0.01) by 26.5% and 35.6%,
respectively, compared to the control (Figure 1E). Schistosomula viability was significantly decreased
(p ≤ 0.01) by all treatments at this timepoint, with the biggest decrease seen in the anti-SmChE cocktail
IgG-treated group (Figure 1F).
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3.2. Effects of Anti-SmChE Antibodies on Adult Worms
The effects of anti-SmChE antibodies on S. mansoni adult worms as also tested. Freshly perfused
worms cultured in the presence of anti-SmAChE1, anti-SmAChE3, or a cocktail of all three anti-SmChEs,
showed no significant inhibition of AChE or BChE activity at 2 h post-treatment, compared to controls.
After 24 h treatment, however, all anti-SmChE IgG-treated groups showed a significant inhibition
of AChE and BChE activity, with the anti-SmChE cocktail IgG-treated group displaying the greatest
inhibition of AChE activity (Figure 2A,B). The rate of glucose uptake over 24 h was also measured at
this timepoint and all antibody treatments significantly reduced the glucose uptake in adult worms,
compared with naïve IgG-treated controls, again with the anti-SmChE cocktail IgG-treated group
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displaying the greatest inhibition (Figure 2C). To determine if anti-SmChE antibodies can play a role
in killing adult worms, the antibody experiment was repeated with ten pairs of adult worms per
treatment and worm viability post-treatment was assessed. Consistent with inhibition of AChE activity
and glucose uptake, the cocktail of anti-SmChE antibodies was the most effective at killing (all worms
dead at day 7 post-treatment), compared to controls (Figure 2D).
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3.3. Antibody Responses to SmChEs during the Course of Infection and Following PZQ Treatment in Mice
Antibody responses to all SmChEs were significantly higher in infected mice than before infection
and increased as infection progressed (Figure 3A). In a separate experiment, all anti-SmChE IgG
responses were shown to significantly increase (p ≤ 0.001) after PZQ treatment (Figure 3B).
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3.4. Vaccine Efficacy of Recombinant SmChEs in a Mouse Model of Schistosomiasis
In both vaccine trials, all four groups of mice immunized with SmChEs, either in isolation or as a
combination, showed a significant decrease in worm burden (28–39%), compared to controls, with
the SmChE cocktail-vaccinated group displaying the highest reduction in trial 1 and 2 of 39% (p ≤
0.0009) and 38% (p ≤ 0.0001), respectively (Figure 4A,B). Compared to controls, significant decreases in
liver egg burdens (expressed as eggs per gram—EPG) were observed for all groups across both trials
(13–46%), except for the SmAChE1-vaccinated group in trial 1. When averaged over both trials, liver egg
burdens in the cocktail-vaccinated group showed the greatest reduction (Figure 4C,D). Intestinal egg
burdens (expressed as EPG—only determined for trial 2) were significantly reduced for all vaccinated
groups, compared to controls, with the greatest reduction seen in the group vaccinated with the SmChE
cocktail (33%, p ≤ 0.001). (Figure 4E). Egg viability (only assessed for trial 2), as determined by egg
hatching from liver homogenates, was significantly reduced in the groups vaccinated with the SmChE
cocktail (40%, p ≤ 0.01) and SmAChE2 (46%, p ≤ 0.01) (Figure 4F). While there was no significant
reduction in glucose uptake for worms from any of the vaccinated groups, compared to controls,
the glycogen content of worms from all vaccinated groups was significantly lower (24–52%, p ≤ 0.001)
than worms from the control group (Figure 5A). A significant reduction in worm length (30%-50%)
was also observed between worms from all vaccinated groups compared to worms from the control
group (Figure 5B). As with the parasitology burden data, worms from the cocktail-vaccinated group
showed the greatest decrease in glycogen content and body length. The glucose uptake, glycogen
content, and worm size were not significantly different between control and vaccinated groups in trial
2. Serum AChE and BChE activity was also not significantly different between control and vaccinated
mice (only measured for trial 2) (Figure S1A,B).
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Figure 4. Vaccine efficacy of recombinant SmChEs in a mouse model of schistosomiasis. Graphs show
parasitology burdens from vaccinated and control mice. (A) Trial 1 adult worms. (B) Trial 2 adult worms.
(C) Trial 1 liver eggs per gram (EPG). (D) Trial 2 liver EPG. (E) Trial 2 intestinal EPG. (F) Hatching
viability of eggs obtained from the pooled livers of control and vaccinated mice from trial 2. Data are
the average of ten replicate counts ± SEM of hatched miracidia. Significance and percent reductions
(if any) for all parameters are measured relative to the control group. Significance determined by the
student’s t test, where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Figure 5. Effect of SmChE vaccination on glycogen storage in, and the size of, S. mansoni adult worms.
(A) Triton-X-100 extracts were made from five pairs of worms freshly perfused from each vaccinated
or control group and the glycogen content in these extracts was measured. Plotted data are the
average of triplicate biological and technical experiments ± SEM. (B) Worm sizes (mm) were assessed
by randomly selecting and measuring (ImageJ) at least 20 worms from each group. Significance
and percent reductions (if any) for both parameters were measured relative to the control group.
Differences for both experiments were measured by the student’s t test, where ** p ≤ 0.01 and *** p ≤
0.001.
3.5. Antibody Responses in Vaccinated Mice
Moderate to high (>1,000,000) anti-SmChE endpoint titers were seen in the pre-challenge serum
of all mice in all vaccinated groups. Post-challenge titers in all groups were four- to ten-fold lower
than pre-challenge titers (Tables S1 and S2). There was no correlation between pre-challenge titers and
worm burdens in any groups.
4. Discussion
Surface-exposed proteins and secreted proteins are effective targets for vaccine development in
schistosomes due to their capacity for interaction with host antibodies [20,21]. In this regard, SmChEs
are promising candidates, as we have shown in previous immunolocalization studies of S. mansoni that
SmAChE1, SmBChE1, and SmAChE2 are expressed in the tegument of adult worms and schistosomula
and proteomic analysis of S. mansoni excretory/secretory (ES) products has confirmed the presence
of SmAChE1 and SmBChE1 [8]. Furthermore, RNAi-mediated silencing of all three SmChE genes,
both individually and in combination, significantly decreased the schistosomula viability in vitro and
parasite survival in vivo [8], implying that these genes are essential for proper worm development
and function. Moreover, recent protein array studies have demonstrated high levels of circulating
antibodies to SmBChE1 in individuals exhibiting drug-induced resistance and a low pathology reaction
to schistosomiasis, implicating these antibodies in a protective anti-schistosomal response [10,11].
Given that SmChEs are accessible to antibody attack and are enzymatically functional [8], catalytic
activity can be used to measure the effectiveness of antibody binding as the interaction between
enzymes and their corresponding antibodies generally leads to a complete or partial reduction in
their enzymatic activity [22–24]. The data presented herein show that antibodies against recombinant
SmChEs are capable of inhibiting surface (and, in the case of SmAChE1 and SmBChE1, secreted)
enzymatic activities in both schistosomula and adult worms, which is similar to previous studies
that have used antibodies raised against parasite-derived AChE to inhibit AChE activity on intact
S. mansoni [25], Necator americanus [26], Dictyocaulus viviparus [27], and Electrophorus electricus [28].
The inhibitory effect of antibodies is potentially due to steric hindrance, potentially blocking substrate
access to the peripheral anionic site or catalytic gorge of AChE. Indeed, previous studies on rabbit [29],
human [30], and bovine [31] AChE have documented the AChE-inhibitory ability of antibodies raised
against epitopes other than AChE-active sites.
Consistent with the effects of RNAi-mediated smche gene silencing [8], antibody-mediated SmChE
inhibition resulted in a significant decrease in parasite viability. We posit that this mode of enzyme
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inhibition was the cause of eventual parasite death as schistosomula were still viable, compared to
controls, at 2 h after antibody treatment, despite a significant decrease in ChE activity; it was not
until after a much longer exposure (14 h) to anti-SmChE antibodies that the parasite viability was
significantly lower.
Glucose uptake in adult worms was also significantly reduced by anti-SmChE antibody treatment.
The cholinergic action of surface AChE has been implicated in mediation of the glucose scavenging
mechanism in schistosomes [12], AChE-inhibitory metal complexes reduce glucose import in the
parasites [13], and we and others have shown that RNAi-mediated silencing of schistosome che
genes lessens the uptake of glucose by these parasites [8,14], so it is possible that antibody-mediated
impairment of AChE involvement in the glucose uptake pathway is the cause of this effect. It may
be that there is some redundancy in the cholinergic functioning of these molecules (even BChEs, like
SmBChE1, can perform a cholinergic role in situations of AChE deficiency [32]), so collective inhibition
of the molecules is required to produce a functional deficit. Additionally, given the multiple proposed
functions for parasite ChEs [6,33], it is possible that the neutralization of multiple enzymatic targets
more profoundly interrupts varied processes of parasite biology than just cholinergic transmission.
Given the relative cytotoxic potential of antibodies against all three SmChEs, as opposed to any
single SmChE, we decided to test the efficacy of this antigen cocktail as a vaccine in a mouse model
of schistosomiasis. The vaccine efficacy of each individual SmChE was also tested to investigate the
relative anti-parasitic effects of each SmChE over the cocktail or one another.
Mice vaccinated with the cocktail of SmChE antigens displayed the highest level of protection
against experimental schistosomiasis, showing the greatest reductions in every parameter tested.
An additive protective effect was not readily apparent, however, as protection levels were not
significantly different from groups vaccinated with single antigens. Of the groups vaccinated with
individual SmAChEs, the SmAChE2-vaccinated group engendered the highest levels of protection.
Similar results were reported in a test on the vaccine efficacy of a recombinant AChE from Schistosoma
japonicum [14]. Furthermore, vaccine trials using purified secretory AChE from the nematodes
Trichostrongylus colubriformis and Dictyocaulus viviparous have resulted in significant protection in
animal models [34,35]. It should be noted that schistosomes and other helminth parasites have complex
life cycles involving more than one host, so rely on passage of their eggs from the definitive host into
the environment to continue their life cycle and transmit disease. Accordingly, mathematical modeling
supports the view that a vaccine inducing even partial protection would decrease the parasite egg
load in the environment, contributing to the reduction of schistosome infections and interrupting
transmission in endemic areas [1,36].
Egg burdens did not concomitantly decrease with worm burdens, but there were significant
reductions in egg viability in all but the SmAChE1-vaccinated group, which is an observation we have
previously reported when testing the in vivo anti-schistosomal efficacy of AChE-inhibitory drugs [13].
Studies in rats and honey bees have observed abdominal spasms and involuntary muscle contractions
when AChE inhibitors have been administered to these organisms [37,38], so a possible explanation
for this “less than expected” decrease in egg number but significant reduction in viability could be
that ova are being prematurely released as a result of antibody-mediated AChE inhibition affecting
reproductive tract motility. It could also be that ChE vaccination affected the fecundity and egg
maturity given the significantly smaller size of worms recovered from vaccinated groups, compared to
controls. Indeed, previous studies on insects demonstrated that the suppression of AChE expression
considerably reduced the weight and length of surviving organisms [39–41] and severely affected
the hatching ability of the eggs laid [39,42]. These reports have suggested that dysregulated cell
proliferation and apoptosis during larval growth may be reasons for such phenotypic effects attributed
to the absence of AChE, although such a link in trematodes remains to be established. Finally, parasites
recovered from vaccinated mice had significantly depleted glycogen stores. Reduced glycogen content
and glucose uptake have been previously observed in worms treated with AChE-inhibitory drugs
in vitro [13] and attributed to interference with the tegumental AChE-mediated glucose scavenging
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pathway [12] through the inhibition of this enzyme. It could be that the same effect is being orchestrated
by the antibody-mediated inhibition of AChE (which would be consistent with the results of in vitro
antibody-based experiments), forcing the parasite to rely on its glycogen stores, rather than the
scavenging of exogenous glucose, for nutrition.
Even though immunization with SmChEs induced high antibody titers, these antibody levels
were not sustained during the course of infection, with titers at necropsy dropping between four- and
ten-fold from pre-challenge levels. This would seem to indicate that the specific antibody response
induced by immunization was not augmented by natural infection, which is a hypothesis corroborated
by the generation of modest anti-SmChE titers during the course of parasite infection in a separate
experiment. That being said, the SmChEs used in this study were still capable of inducing moderate
levels of protection in the face of modest antibody titers. Treatment with PZQ has been shown to induce
antibody-mediated resistance to schistosomiasis in humans through the exposure of parasite antigens
to the immune system (and subsequent generation of an antibody response) as a result of tegument
damage [43] and protein array studies conducted by us have shown that antibodies to SmBChE1 are
significantly upregulated in resistant individuals [10]. The upregulation of SmChE immune responses
following PZQ treatment has been verified in this study. Given that an effective anti-schistosomal
vaccine strategy would ideally be linked with chemotherapy [10], it is possible that the vaccine efficacy
of antigens such as the ones described here could be increased by vaccination after PZQ treatment due to
the augmentation of an already upregulated immune response. The current World Health Organisation
(WHO) objective regarding schistosomiasis is to eliminate disease morbidity and mortality as a public
health problem—defined by reaching a prevalence of ≤5% and ≤1% of heavy-intensity infections,
respectively, in school-age children—in the coming decade [44]. Vaccine-linked chemotherapy has
been deemed one the most effective control measures for combating the disease, with this strategy
combining the mainstay of schistosomiasis intervention (mass administration of PZQ) with the more
long-term benefits of vaccination, and recent modeling has predicted that chemotherapy linked with a
vaccine that has an effective duration of protection is the best intervention strategy for achievement of
the WHO’s goals to significantly reduce the burden of disease caused by schistosomiasis [44].
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